Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
Titanium dioxide in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm is restricted in cosmetic products under Annex III of the EU Cosmetics Regulation (EC) 1223/2009.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 70/100 (high) · high confidence.
Regional restrictions
Prevalence of TITANIUM DIOXIDE in our catalog (epa_cpdat).
Products
41,617
Brands
6
Typical roles
Catalog
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Food use
Food-use source coverage is present in the current record.
The ingredient appears in food-oriented source coverage or allowed-use references, which makes food use easier to support than a context with no domain signal at all.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
EU
EC
Annex III of EU Cosmetics Regulation (EC) 1223/2009: substances which cosmetic products must not contain except subject to the restrictions laid down. Product types: (a) face products in loose powder form (b) hair aerosol spray products (c) other products Maximum concentration: (a) 25 %; (b) 1,4 % for general consumers, and 1.1 % for professional use. Other conditions: a) (b) Only in the pigmentary form (c) Not to be used in applications that may lead to exposure of the end-user’s lungs by inhalation
EU
EC
Annex IV of EU Cosmetics Regulation (EC) 1223/2009: colorants allowed in cosmetic products. Conditions of use and warnings: — Purity criteria as set out in Commission Directive 95/45/E (E 171) — Titanium dioxide in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm, to be used in compliance with Annex III, No 321 (For use as a UV filter, see Annex VI, No 27)
Cicaplast Baume B5+
La Roche Posay
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
EU
EC
Annex VI of EU Cosmetics Regulation (EC) 1223/2009: UV filters allowed in cosmetic products. Maximum concentration: 25%* *: In case of combined use of Titanium Dioxide and Titanium Dioxide (nano), the sum shall not exceed the limit given in column g (Maximum concentration in ready for use preparation) Other conditions: Titanium dioxide in powder form containing 1 % or more of particles with aerodynamic diameter ≤ 10 μm, to be used in compliance with Annex III, No 321. For the product types under letter (c) of column (f) in Annex III, No 321, the maximum concentration in ready for use preparation provided in column (g) of this entry applies. (For use as a colourant, see Annex IV, No 143)
US
EPA
EPA CPDat observed this chemical in 41617 composition records across product categories including Construction and building materials, Raw materials, Furniture and furnishings. EPA CPDat classifies this chemical for functional uses including Pigment, Dye, Brightener.
US
FDA
Route: BUCCAL; Dosage form: FILM; Maximum daily exposure: 3 mg
US
FDA
Route: BUCCAL; Dosage form: FILM, SOLUBLE; Maximum daily exposure: 11 mg
US
FDA
Route: BUCCAL; Dosage form: GUM, CHEWING; Maximum daily exposure: 182 mg
US
FDA
Route: DENTAL; Dosage form: PASTE, DENTIFRICE; Potency: 0.4 %w/w
US
FDA
Route: INTRAUTERINE; Dosage form: SUPPOSITORY, EXTENDED RELEASE; Potency: 1 mg
US
FDA
Route: OPHTHALMIC; Dosage form: INSERT, EXTENDED RELEASE; Potency: 0.4 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE; Maximum daily exposure: 72 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, COATED; Maximum daily exposure: 17 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, COATED PELLETS; Potency: 4.4 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, COATED, EXTENDED RELEASE; Potency: NA
US
FDA
Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE; Maximum daily exposure: 55 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE PELLETS; Maximum daily exposure: 24 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, EXTENDED RELEASE; Maximum daily exposure: 67 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, LIQUID FILLED; Maximum daily exposure: 12 mg
US
FDA
Route: ORAL; Dosage form: FILM, SOLUBLE; Maximum daily exposure: 2 mg
US
FDA
Route: ORAL; Dosage form: GRANULE, FOR SUSPENSION; Maximum daily exposure: 143 mg
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SUSPENSION; Maximum daily exposure: 297 mg
US
FDA
Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 113 mg
US
FDA
Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 232 mg
US
FDA
Route: ORAL; Dosage form: TABLET, COATED; Maximum daily exposure: 49 mg
US
FDA
Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Maximum daily exposure: 66 mg
US
FDA
Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Maximum daily exposure: 90 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED; Maximum daily exposure: 36 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED, EXTENDED RELEASE; Maximum daily exposure: 11 mg
US
FDA
Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 6 mg
US
FDA
Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; Maximum daily exposure: 42 mg
US
FDA
Route: RESPIRATORY (INHALATION); Dosage form: CAPSULE; Potency: NA
US
FDA
Route: RESPIRATORY (INHALATION); Dosage form: POWDER; Potency: 2 mg
US
FDA
Route: TOPICAL; Dosage form: CREAM; Maximum daily exposure: 80 mg
US
FDA
Route: TOPICAL; Dosage form: OINTMENT; Potency: 5 %w/w
US
FDA
Route: TOPICAL; Dosage form: SHAMPOO, SUSPENSION; Potency: 3 %w/v
US
FDA
Route: TOPICAL; Dosage form: SYSTEM; Maximum daily exposure: 420 mg
US
FDA
Route: TRANSDERMAL; Dosage form: FILM, EXTENDED RELEASE; Potency: NA
US
FDA
FDA NDC lists this ingredient in 1 active drug products and 1 total products.
US
FDA
FDA NDC lists this ingredient in 2721 active drug products and 2777 total products.
US
FDA
openFDA substance registry classifies this ingredient as chemical.